多索茶碱、罗红霉素、桉柠蒎肠溶软胶囊联合治疗支气管扩张的临床效果
|
摘要
目的探讨多索茶碱、罗红霉素、桉柠蒎肠溶软胶囊联合治疗支气管扩张的临床效果。方法分析我院2016年2月～2018年5月收治的60例支气管扩张患者的临床资料,依据随机纸片法分为对照组(30例)和观察组(30例)。对照组患者采用小剂量罗红霉素治疗,观察组采用多索茶碱、罗红霉素、桉柠蒎肠溶软胶囊联合治疗。比较两组支气管扩张患者治疗前后的肺功能、呼吸困难评分和影像学评分情况,观察两组支气管扩张患者的临床疗效情况。结果两组支气管扩张患者治疗前1 s用力呼气容积(FEV_1)、用力肺活量(FVC)、呼气流量峰值(PEF)呼吸困难评分和影像学评分比较,差异均无统计学意义(P>0.05)。两组患者治疗后的FEV_1、FVC、PEF均高于治疗前,呼吸困难评分和影像学评分均低于治疗前,差异有统计学意义(P<0.05)。观察组患者治疗后的FEV_1、FVC、PEF均高于对照组,呼吸困难评分和影像学评分均低于对照组,差异有统计学意义(P<0.05)。观察组支气管扩张患者的临床治疗总有效率高于对照组,差异有统计学意义(P<0.05)。结论多索茶碱、罗红霉素、桉柠蒎肠溶软胶囊联合治疗支气管扩张患者效果显著,肺功能明显提高,呼吸困难评分和影像学评分明显降低,值得临床推广应用。
Objective To investigate the clinical effect of Doxofylline, Roxithromycin and Eucalyptol Enteric Soft Capsule in the combination treatment of bronchiectasis. Methods The clinical data of 60 patients with bronchiectasis admitted to our hospital from February 2016 to May 2018 were analyzed. They were divided into the control group and the observation group by the random paper strip, 30 cases in each group. The patients in the control group were treated with low dose Roxithromycin, while the patients in the observation group were treated with Doxofylline, Roxithromycin and Eucalyptol Enteric Soft Capsule. The lung function, dyspnea score and imaging score of the patients with bronchiectasis before and after treatment were compared. The clinical efficacy in the two groups was observed. Results There were no significant differences in the first second forced expiratory volume(FEV_1), forced vital capacity(FVC), peak expiratory flow(PEF), dyspnea score or imaging score between the two groups before treatment(P>0.05). After treatment,the values of FEV_1,FVC and PEF in the two groups were higher than those before treatment, and the dyspnea and imaging scores were lower than those before treatment, with statistical significance(P <0.05). Compared with the control group, the FEV_1, FVC and PEF of the observation group were higher, and the dyspnea and imaging scores were lower,with statistical significance(P<0.05). The total effectiveness rate of clinical treatment of bronchiectasis patients in the observation group was higher than that in the control group, with statistical significance(P <0.05). Conclusion The combination of Doxofylline, Roxithromycin, and Eucalyptol Enteric Soft Capsule in the treatment of patients with bronchiectasis can remarkably improves the lung function, reduces the dyspnea and imaging scores, and is worthy of clinical application and promotion.
Objective To investigate the clinical effect of Doxofylline, Roxithromycin and Eucalyptol Enteric Soft Capsule in the combination treatment of bronchiectasis. Methods The clinical data of 60 patients with bronchiectasis admitted to our hospital from February 2016 to May 2018 were analyzed. They were divided into the control group and the observation group by the random paper strip, 30 cases in each group. The patients in the control group were treated with low dose Roxithromycin, while the patients in the observation group were treated with Doxofylline, Roxithromycin and Eucalyptol Enteric Soft Capsule. The lung function, dyspnea score and imaging score of the patients with bronchiectasis before and after treatment were compared. The clinical efficacy in the two groups was observed. Results There were no significant differences in the first second forced expiratory volume(FEV_1), forced vital capacity(FVC), peak expiratory flow(PEF), dyspnea score or imaging score between the two groups before treatment(P>0.05). After treatment,the values of FEV_1,FVC and PEF in the two groups were higher than those before treatment, and the dyspnea and imaging scores were lower than those before treatment, with statistical significance(P <0.05). Compared with the control group, the FEV_1, FVC and PEF of the observation group were higher, and the dyspnea and imaging scores were lower,with statistical significance(P<0.05). The total effectiveness rate of clinical treatment of bronchiectasis patients in the observation group was higher than that in the control group, with statistical significance(P <0.05). Conclusion The combination of Doxofylline, Roxithromycin, and Eucalyptol Enteric Soft Capsule in the treatment of patients with bronchiectasis can remarkably improves the lung function, reduces the dyspnea and imaging scores, and is worthy of clinical application and promotion.
引文
[1]吴建辉,刘志新,彭志文,等.桉柠蒎联合小剂量罗红霉素治疗稳定期支气管扩张疗效观察[J].临床肺科杂志,2018,23(2):308-311.
[2]Altenburg J,de Graaff CS,Stienstra Y,et al.Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis:the BAT randomized controlled trial[J].JAMA,2013,309(12):1251-1259.
[3]杨冬梅.长期小剂量罗红霉素联合氨溴索治疗支气管扩张症的疗效观察[J].西南军医,2018,20(1):26-28.
[4]Shi ZL,Peng H,Hu XW,et al.Effectiveness and safety of macrolides in bronchiectasis patients:a meta-analysis and systematic review[J].Pulm Pharmacol Ther,2014,28(2):171-181.
[5]殷晓娜,宋卫东.慢性阻塞性肺疾病评估测试方法的比较研究[J].临床肺科杂志,2017,22(4):645-649.
[6]Porcel JM,Pardina M,Bielsa S,et al.Derivation and validation of a CT scan scoring system for discriminating malignant from benign pleural effusions[J].Chest,2015,147(2):513-519.
[7]韩慧.口服小剂量罗红霉素对支气管扩张长期治疗的效果观察[J].北方药学,2016,13(5):13-14.
[8]Mehmet K,Aydin K,Suat K,et al.Evaluation of effects of bronchiectasis on bronchial artery diameter with multidetector computed tomography[J].Acta Radiol,2014,55(2):171-178.
[9]薛雨松,高永斌,王张莹.罗红霉素联合氨茶碱对支气管扩张的疗效[J].临床肺科杂志,2016,21(4):722-725.
[10]Singleton RJ,Valery PC,Morris P,et al.Indigenous children rom three countries with non-cystic fibrosis chronic suppurative lung disease/bronchiectasis[J].Pediatr Pulm,2014,49(2):189-200.
[11]Nawa T,Yokozawa M,Takamuro M,et al.Plastic bronchitis developing 5 years after fontan procedure in a girl with kartagener′s syndrome[J].Ediatr Cardiol,2012,33(5):846-849.
[12]Anwar GA,McDonnell MJ,Worthy SA,et al.Phenotyping adults with non-cystic fibrosis bronchiectasis:a prospective observational cohort study[J].Resp Med,2013,107(7):1001-1007.
[13]王永仓,孙晓光,孙砚诚,等.脾氨肽联合小剂量罗红霉素对支气管扩张稳定期疗效观察[J].河北医学,2016,22(2):295-296.
[14]晋俊辉.脾氨肽联合小剂量罗红霉素治疗支气管扩张稳定期患者效果观察[J].河南医学研究,2018,27(12):2239-2240.
[15]尹爱明,贺细梅,孙凯,等.小剂量罗红霉素对支气管扩张症NF-κB通路及气道炎症的影响以及临床疗效研究[J].临床肺科杂志,2016,21(11):1955-1957.
[16]周书蕾.小剂量罗红霉素联合氨茶碱治疗支气管扩张的疗效观察[J].海峡药学,2017,29(8):140-141.
[17]李秋明,杨培文,利桂河,等.支气管扩张患者长期应用小剂量罗红霉素联合氨茶碱的疗效分析[J].中国医学创新,2015,12(1):55-57.
[18]王永仓,孟婷,孙莹,等.低剂量罗红霉素和联合脾胺肽对支气管扩张患者外周血INF-γ、IL-4及CD4+、CD8+细胞影响及其临床疗效评价[J].中国卫生检验杂志,2017,27(20):2944-2946,2949.
[19]Begrow F,Bckenholt C,Ehmen M,et al.Effect of myrtol standardized and other substances on the respiratory tract:ciliary beat frequency and mucociliary clearance as parameters[J].Adv Ther,2012,29(4):350-358.
[2]Altenburg J,de Graaff CS,Stienstra Y,et al.Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis:the BAT randomized controlled trial[J].JAMA,2013,309(12):1251-1259.
[3]杨冬梅.长期小剂量罗红霉素联合氨溴索治疗支气管扩张症的疗效观察[J].西南军医,2018,20(1):26-28.
[4]Shi ZL,Peng H,Hu XW,et al.Effectiveness and safety of macrolides in bronchiectasis patients:a meta-analysis and systematic review[J].Pulm Pharmacol Ther,2014,28(2):171-181.
[5]殷晓娜,宋卫东.慢性阻塞性肺疾病评估测试方法的比较研究[J].临床肺科杂志,2017,22(4):645-649.
[6]Porcel JM,Pardina M,Bielsa S,et al.Derivation and validation of a CT scan scoring system for discriminating malignant from benign pleural effusions[J].Chest,2015,147(2):513-519.
[7]韩慧.口服小剂量罗红霉素对支气管扩张长期治疗的效果观察[J].北方药学,2016,13(5):13-14.
[8]Mehmet K,Aydin K,Suat K,et al.Evaluation of effects of bronchiectasis on bronchial artery diameter with multidetector computed tomography[J].Acta Radiol,2014,55(2):171-178.
[9]薛雨松,高永斌,王张莹.罗红霉素联合氨茶碱对支气管扩张的疗效[J].临床肺科杂志,2016,21(4):722-725.
[10]Singleton RJ,Valery PC,Morris P,et al.Indigenous children rom three countries with non-cystic fibrosis chronic suppurative lung disease/bronchiectasis[J].Pediatr Pulm,2014,49(2):189-200.
[11]Nawa T,Yokozawa M,Takamuro M,et al.Plastic bronchitis developing 5 years after fontan procedure in a girl with kartagener′s syndrome[J].Ediatr Cardiol,2012,33(5):846-849.
[12]Anwar GA,McDonnell MJ,Worthy SA,et al.Phenotyping adults with non-cystic fibrosis bronchiectasis:a prospective observational cohort study[J].Resp Med,2013,107(7):1001-1007.
[13]王永仓,孙晓光,孙砚诚,等.脾氨肽联合小剂量罗红霉素对支气管扩张稳定期疗效观察[J].河北医学,2016,22(2):295-296.
[14]晋俊辉.脾氨肽联合小剂量罗红霉素治疗支气管扩张稳定期患者效果观察[J].河南医学研究,2018,27(12):2239-2240.
[15]尹爱明,贺细梅,孙凯,等.小剂量罗红霉素对支气管扩张症NF-κB通路及气道炎症的影响以及临床疗效研究[J].临床肺科杂志,2016,21(11):1955-1957.
[16]周书蕾.小剂量罗红霉素联合氨茶碱治疗支气管扩张的疗效观察[J].海峡药学,2017,29(8):140-141.
[17]李秋明,杨培文,利桂河,等.支气管扩张患者长期应用小剂量罗红霉素联合氨茶碱的疗效分析[J].中国医学创新,2015,12(1):55-57.
[18]王永仓,孟婷,孙莹,等.低剂量罗红霉素和联合脾胺肽对支气管扩张患者外周血INF-γ、IL-4及CD4+、CD8+细胞影响及其临床疗效评价[J].中国卫生检验杂志,2017,27(20):2944-2946,2949.
[19]Begrow F,Bckenholt C,Ehmen M,et al.Effect of myrtol standardized and other substances on the respiratory tract:ciliary beat frequency and mucociliary clearance as parameters[J].Adv Ther,2012,29(4):350-358.